Iovance Biotherapeutics (NASDAQ: IOVA) affirms 2025 Amtagvi revenue view

Rhea-AI Filing Summary

Iovance Biotherapeutics, Inc. filed a report describing an updated corporate presentation it will use with healthcare conference audiences, analysts, current stockholders, and others. In that presentation, the company states it expects to achieve its previously disclosed full-year 2025 revenue guidance range of $250 to $300 million in the first full calendar year of sales for its therapy Amtagvi. The updated slide deck is provided as Exhibit 99.1 to the report.

Insights

Biotech equity analyst

Iovance reiterates a sizable 2025 Amtagvi revenue target.

Iovance Biotherapeutics indicates through its updated corporate presentation that it continues to expect full-year 2025 revenue between $250 million and $300 million from its first full calendar year of Amtagvi sales. This restates previously disclosed guidance rather than introducing a new numerical target.

The statement signals that management is still publicly aligning expectations with that revenue range, which is meaningful for a commercial-stage biotech product. However, because the range was already communicated before and no new comparative metrics or changes to the outlook are provided in the excerpt, the information is best viewed as a confirmation of prior guidance.

Subsequent company communications and future filings covering results for 2025 will show how actual Amtagvi revenue compares with the $250–$300 million expectation described in this presentation.

false 0001425205 0001425205 2026-01-09 2026-01-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): January 9, 2026

IOVANCE BIOTHERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State of Incorporation)
001-36860		75-3254381
Commission File Number		(I.R.S. Employer Identification No.)
825 Industrial Road, Suite 100
San Carlos, California		94070
(Address of Principal Executive Offices)		(Zip Code)
(650) 260-7120
(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.000041666 per value	IOVA	The Nasdaq Stock Market, LLC

Item 8.01 Other Events.

On January 9, 2026, Iovance Biotherapeutics, Inc. (the “Company”) updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. The Company’s presentation states that the Company expects to achieve its previously disclosed full-year 2025 revenue guidance range of $250 to $300 million in the first full calendar year of Amtagvi sales. A copy of the Company’s presentation that it intends to use at such events is attached as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Iovance Biotherapeutics, Inc., Corporate Presentation – January 2026
104		Cover Page Interactive Data File (embedded as Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 9, 2026	Iovance Biotherapeutics, Inc.
	By:	/s/ Frederick G. Vogt
		Name:	Frederick G. Vogt, Ph.D., J.D.
		Title:	Interim CEO, President, and General Counsel

FAQ

What did Iovance Biotherapeutics (IOVA) disclose in this 8-K filing?

Iovance Biotherapeutics reported that it updated its corporate presentation used at healthcare conferences and with analysts, stockholders, and others, and filed the deck as Exhibit 99.1.

What revenue guidance did Iovance Biotherapeutics (IOVA) reference for 2025?

The company’s presentation states it expects to achieve its previously disclosed full-year 2025 revenue guidance range of $250 to $300 million in the first full calendar year of Amtagvi sales.

Which product is tied to Iovance Biotherapeutics’ 2025 revenue outlook?

The revenue guidance range of $250 to $300 million is tied to the first full calendar year of sales for Iovance Biotherapeutics’ therapy Amtagvi.

How is Iovance Biotherapeutics sharing the updated information with investors?

Iovance Biotherapeutics is using an updated corporate presentation at healthcare conferences and in meetings with analysts, current stockholders, and others, and has attached it as Exhibit 99.1.

What exhibit in the 8-K contains Iovance Biotherapeutics’ January 2026 presentation?

Exhibit 99.1 is the Iovance Biotherapeutics, Inc. corporate presentation dated January 2026 that includes the revenue expectation for Amtagvi.

On which exchange is Iovance Biotherapeutics (IOVA) common stock listed?

Iovance Biotherapeutics’ common stock, trading under the symbol IOVA, is listed on The Nasdaq Stock Market, LLC.